Joel R Saper: Influence Statistics

Joel R Saper

Joel R Saper

Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA. | Michigan Headache & Neurological Institute, Ann Arbor, MI, USA | Michigan Headache and Neurological ...

Joel R Saper: Expert Impact

Concepts for which Joel R Saper has direct influence: Chronic migraine , Acute treatment , Naproxen sodium , Chronic daily headache , Acute migraine , Episodic migraine , Migraine headache .

Joel R Saper: KOL impact

Concepts related to the work of other authors for which for which Joel R Saper has influence: Chronic migraine , Cluster headache , Botulinum toxin , Acute treatment , Medication overuse .

KOL Resume for Joel R Saper

Year
2022

Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA.

2020

Michigan Headache & Neurological Institute, Ann Arbor, MI, USA

2017

Michigan Headache and Neurological Institute Ann Arbor MI

2016

Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA

2015

Founder & Director of MHNI, Clinical Professor of Neurology, Ann Arbor, Michigan, USA.

Michigan Head Pain & Neurological Institute Ann Arbor MI USA

2013

Michigan Head‐Pain & Neurological Institute Ann Arbor MI USA

2012

From the Headache Research and Treatment Program (J.M.H., A.C.), Department of Neurology, University of California Los Angeles, Los Angeles; Departments of Neurology, Epidemiology, and Population Health, and the Montefiore Headache Center (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Department of Neurology (D.W.D.), Mayo Clinic Arizona, Phoenix; Department of Neurology and the Jefferson Headache Center (S.D.S.), Thomas Jefferson University Hospital, Philadelphia, PA; Michigan Head Pain and Neurological Institute (J.R.S.), Ann Arbor; Swedish Pain Center (S.K.A.), Seattle, WA; Headache Group (P.J.G.), Department of Neurology, University of California, San Francisco; and Danish Headache Center (J.M.H.), Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark.

Michigan Head Pain & Neurological Institute, USA

2010

Michigan Head–Pain and Neurological Institute, USA.

2009

From the Michigan Head‐Pain and Neurological Institute, Ann Arbor, MI, USA

Department of Neurology, Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan

2008

From the Jefferson Headache Center (S.S.), Thomas Jefferson University, Philadelphia, PA; Michigan Head Pain and Neurological Institute (J.S.), Ann Arbor; Child Neurology Associates (F.B.), Atlanta, GA; and Novartis Pharmaceuticals (M.S., K.M., J.D.), East Hanover, NJ.

Michigan State University, USA.

2007

From the Mayo Clinic College of Medicine, Department of Neurology, Scottsdale, AZ, USA (Dr. Dodick); Jefferson Headache Center, Philadelphia, PA, USA (Dr. Silberstein); Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA (Dr. Saper); Diamond Headache Clinic, Chicago, IL, USA (Dr. Freitag); Headache Care Center, Springfield, MO, USA (Dr. Cady); UCLA School of Medicine, Department of Neurology, Los Angeles, CA, USA (Dr. Rapoport); Houston Headache Clinic, Houston, TX, USA (Dr. Mathew); Ortho‐McNeil Janssen, Scientific Affairs, LLC, Titusville, NJ, USA (Drs. Hulihan, Crivera, Rupnow, Mao, Finlayson, and Greenberg)

Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan;

2006

Michigan Head Pain & Neurological Institute, Ann Arbor, USA.

2005

Address all correspondence to Dr. Joel R. Saper, Michigan Head Pain and Neurological Institute, 3120 Professional Drive, Ann Arbor, MI 48104

2004

From the Michigan Head-Pain and Neurological Institute, Ann Arbor.

2003

3120 Professional Drive

From the Departments of Neurology (Drs. Lipton and Bigal) and Epidemiology and Social Medicine (Dr. Lipton), Albert Einstein College of Medicine, Bronx, NY; Department of Neurology (Dr. Silberstein), Thomas Jefferson University School of Medicine, Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA; Michigan Head Pain and Neurological Institute (Dr. Saper), Ann Arbor, MI; The New England Center for Headache (Dr. Bigal), Stamford, CT; and The National Hospital for Neurology and Neurosurgery (Dr. Goadsby), Queen Square, London, UK.

Michigan Head‐Pain and Neurological Institute

Ann Arbor, MI 48104

2002

From Michigan Head‐Pain and Neurological Institute, Ann Arbor

2001

Michigan Head Pain and Neurological Institute, 3120 Professional Dr, Ann Arbor, MI 48104-5131, USA.

2000

Drs. Lake and Saper with the Michigan Head Pain and Neurological Institute, Ann Arbor

From the Head Pain Treatment Unit at Chelsea Community Hospital

Diamond Headache Clinic, Chicago, IL, USA.

1999

From the Michigan Head‐Pain and Neurological Institute, Ann Arbor.

Michigan Head, Pain, and Neurological Institute, Ann Arbor, Michigan 48104, USA.

1997

From the Cleveland Clinic Foundation (Dr. Solomon), Cleveland, OH; the Headache Care Center (Dr. Cady), Springfield, MO; the colorado Neurology and Headache Center (Dr. Klapper), Denver, CO; the Duke University Medical Center, Durham, and Glaxo Wellcome Inc (Dr. Earl), Research Triangle Park, NC; the Michigan Head-Pain and Neurological Institute (Dr. Saper), Ann Arbor, MI; and the Headache Center (Dr. Ramadan), Henry Ford Hospital, Detroit, MI.

Michigan Headache and Neurological Institute, Ann Arbor, MI, USA;

1996

Michigan Head Pain and Neurologic Institute, Ann Arbor;

1995

Michigan Head Pain & Neurological Institute

1994

Michigan Head‐Pain and Neurological Institute, Ann Arbor, Michigan

1992

Michigan Head-Pain and Neurological Institute, Michigan State University, Ann Arbor.

1990

Director, Michigan Head Pain and Neurological Institute, Ann Arbor; Clinical Professor of Medicine (Neurology), Michigan State University, East Lansing, Michigan; and President, American Association for the Study of Headache

1989

Director, Michigan Headache and Neurological Institute, Associate Clinical Professor of Medicine (Neurology), Michigan State University, Ann Arbor, Michigan

1988

Michigan Headache and Neurological Institute, 3120 Professional Drive, Ann Arbor, MI 48104 U.S.A.

1987

Director, Michigan Headache and Neurological Institute, and Associate Clinical Professor of Medicine (Neurology), Michigan State University, Ann Arbor, Michigan

Ann Arbor, MI.

1986

Michigan Headache and Neurological Institute, P.C., Ann Arbor, Michigan, U.S.A.

1983

Director, Michigan Headache and Neurological Institute, Ann Arbor, Michigan

Prominent publications by Joel R Saper

KOL-Index: 19556 . OBJECTIVE: To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain. DESIGN: Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies. SETTING: Private practice, referral centers, and general community. PATIENTS: Migraineurs with moderate or severe headache pain who met ...
Known for Migraine Headache | Aspirin Caffeine | Patients Pain | Nonprescription Combination
KOL-Index: 16693 . OBJECTIVE: To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine. METHODS: This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous ...
Known for Chronic Migraine | Placebo Treatment | Safety Topiramate | 100 Day
KOL-Index: 15961 . OBJECTIVE: To compare the efficacy and tolerability of sumatriptan nasal spray (NS; 5 mg, 10 mg, and 20 mg) with placebo for the treatment of acute migraine in adolescents. METHODS: A randomized, double-blind, placebo-controlled, single-attack study was conducted in 653 US adolescents (12-17 years of age). Patients with at least a 6-month history of migraine, who met International Headache ...
Known for Acute Migraine | Headache Relief | 20 Placebo | 2 Hours
KOL-Index: 15478 . OBJECTIVE: To assess the efficacy of tizanidine hydrochloride versus placebo as adjunctive prophylactic therapy for chronic daily headache (chronic migraine, migrainous headache, or tension-type headache). BACKGROUND: Tizanidine is an alpha2-adrenergic agonist that inhibits the release of norepinephrine at both the spinal cord and brain, with antinociceptive effects that are independent of ...
Known for Chronic Daily Headache | Tizanidine Placebo | 4 Weeks | Tension Type
KOL-Index: 14785 . CONTEXT: Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention. OBJECTIVE: To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial. DESIGN, SETTING, AND PATIENTS: A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North ...
Known for Migraine Prevention | Patients Topiramate | Randomized Controlled | 200 Placebo
KOL-Index: 14781 . BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with ...
Known for Amg 334 | Episodic Migraine | 2 Trial | Monoclonal Antibodies
KOL-Index: 13785 . BACKGROUND: Preliminary work suggests that single-pulse transcranial magnetic stimulation (sTMS) could be effective as a treatment for migraine. We aimed to assess the efficacy and safety of a new portable sTMS device for acute treatment of migraine with aura. METHODS: We undertook a randomised, double-blind, parallel-group, two-phase, sham-controlled study at 18 centres in the USA. 267 ...
Known for Acute Treatment | Migraine Aura | Sham Stimulation | Transcranial Magnetic
KOL-Index: 13774 . OBJECTIVE: To compare gabapentin with placebo for use as a prophylactic agent in patients with migraine (with or without aura). STUDY DESIGN AND TREATMENT: After screening, a 4-week, single-blind, placebo baseline period was followed by a 12-week, double-blind, treatment period. The 12-week treatment period consisted of a 4-week titration phase and an 8-week stable-dosing phase. During the ...
Known for Patients Migraine | Gabapentin Placebo | 4 Week | Study Medication
KOL-Index: 13563 . OBJECTIVE: Currently, no drugs are Food and Drug Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents. METHODS: Adolescents (12-17 years of age) with a >/=6-month history of migraine were assigned randomly to receive 16 weeks of daily treatment with ...
Known for Migraine Prevention | Efficacy Safety | 17 Years | 50 Day
KOL-Index: 12641 . OBJECTIVE: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine. METHODS: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy-1 (PROMISE-1) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with ...
Known for Episodic Migraine | Eptinezumab 100 | Preventive Treatment | Mmds Weeks
KOL-Index: 12624 . OBJECTIVE: To determine if repetitive sphenopalatine ganglion (SPG) blocks with 0.5% bupivacaine delivered through the Tx360(®) are superior in reducing pain associated with chronic migraine (CM) compared with saline. BACKGROUND: The SPG is a small concentrated structure of neuronal tissue that resides within the pterygopalatine fossa (PPF) in close proximity to the sphenopalatine foramen ...
Known for Acute Treatment | Sphenopalatine Ganglion | Bupivacaine Saline | Spg Blockade
KOL-Index: 12339 . OBJECTIVE: The primary objective of this study was to compare the efficacy and tolerability of topiramate and amitriptyline in the prophylaxis of episodic migraine headache. METHODS: This was a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority study. Adults with 3 to 12 migraines per month were randomized in a 1:1 ratio to receive an initial dose ...
Known for Migraine Prevention | Topiramate Amitriptyline | Life Msq | Weight Loss
KOL-Index: 11739 . OBJECTIVE: This study assessed the efficacy of diclofenac potassium for oral solution, a novel water-soluble buffered powder formulation, versus placebo for the acute treatment of migraine. Diclofenac potassium for oral solution has a time to maximum plasma concentration (Tmax) of 15 minutes, suggesting the potential for a rapid onset of therapeutic effects. METHODS: This was a randomized, ...
Known for Oral Solution | Acute Treatment | Diclofenac Potassium | 30 Minutes
KOL-Index: 11484 . OBJECTIVE: To evaluate non-invasive vagus nerve stimulation (nVNS) as an acute cluster headache (CH) treatment. BACKGROUND: Many patients with CH experience excruciating attacks at a frequency that is not sufficiently addressed by current symptomatic treatments. METHODS: One hundred fifty subjects were enrolled and randomized (1:1) to receive nVNS or sham treatment for ≤1 month during a ...
Known for Acute Treatment | Nvns Sham | Cluster Headache | Ech Cch
KOL-Index: 11203 . OBJECTIVE: To assess the efficacy and tolerability of subcutaneous dihydroergotamine mesylate (DHE-45) vs subcutaneous sumatriptan succinate (Imitrex) for the treatment of acute migraine with or without aura. DESIGN: Double-blind, randomized trial with parallel treatment arms. SETTING: Clinics and private neurology practices. SUBJECTS: Patients of either sex, with migraine with or without ...
Known for Subcutaneous Dihydroergotamine | Acute Migraine | 24 Hours | Headache Relief

Key People For Chronic Migraine

Top KOLs in the world
#1
Richard B Lipton
chronic migraine united states acute treatment
#2
Stephen David Silberstein
chronic migraine cluster headache acute treatment
#3
David William Dodick
chronic migraine cluster headache acute treatment
#4
Peter James Goadsby
cluster headache chronic migraine acute treatment
#5
Hanschristoph C Diener
atrial fibrillation cluster headache chronic migraine
#6
Marcelo Eduardo Bigal
chronic migraine preventive treatment temporomandibular disorders

Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA. | Michigan Headache & Neurological Institute, Ann Arbor, MI, USA | Michigan Headache and Neurological Institute Ann Arbor MI | Michigan Head Pain and Neurological Institute, Ann Arbor